We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
- Authors
Dias, M M; Pignon, J-P; Karapetis, C S; Boige, V; Glimelius, B; Kweekel, D M; Lara, P N; Laurent-Puig, P; Martinez-Balibrea, E; Páez, D; Punt, C J A; Redman, M W; Toffoli, G; Wadelius, M; McKinnon, R A; Sorich, M J
- Abstract
To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1*28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1*28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1*28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1*28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1*28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1*28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.
- Subjects
IRINOTECAN; ALLELES; CANCER chemotherapy; META-analysis; PHARMACOGENOMICS; DRUG toxicity; THERAPEUTICS
- Publication
Pharmacogenomics Journal, 2014, Vol 14, Issue 5, p424
- ISSN
1470-269X
- Publication type
Article
- DOI
10.1038/tpj.2014.16